South Holland reidents urged not to have New Year parties Published: 16:13, 24 December 2020
Residents in South Holland are being warned not to start the new year with a bang as concerns rise over unsafe gatherings which go against tiered restrictions.
As South Holland remains in tier 3, large groups of more than six people are not permitted to meet socially in any setting. But there are growing fears that people will ignore the restrictions and gather to see in the new year.
The plea for residents to be sensible comes after Sutton Bridge Parish Council became aware of plans by a group to gather in the villageâs Memorial Park for an unlicensed and unauthorised firework display.
Se, en kunde på julemarkedet! aftenbladet.no - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aftenbladet.no Daily Mail and Mail on Sunday newspapers.
Sutton St James drama graduate stars online in Mr Beaver s Advent Series Published: 06:00, 19 December 2020
A drama graduate from Sutton St James is lighting up childrenâs lives online with a daily diary from a much-loved childrenâs character.
Gaby Ward (21) is spreading some much-needed Christmas cheer up until the big day by acting out a set of short stories, called Mr Beaverâs Advent Series.
Based on the character from The Lion, The Witch and The Wardrobe, part of The Chronicles of Narnia series written by C. S. Lewis, Gaby describes each one-minute to three-minute episode as a way âto make people a bit happier in rough timesâ.
Dec 14, 2020 06:15 UTC
Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine Storm WILMINGTON, Del. (Business Wire) Incyte (Nasdaq:INCY) today announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi
®), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet its primary endpoint. Initial data show that there was no reduction in the proportion of patients receiving ruxolitinib plus SoC who experienced severe complications including death, respiratory failure requiring mechanical ventilation or admission to the intensive care unit (ICU) care by Day 29, compared to SoC treatment alone (12.0% vs. 11.8% [OR: 0.91 [95% CI: 0.48-1.73],
Ex-Valve exec leads J J Abrams new game development studio tweaktown.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tweaktown.com Daily Mail and Mail on Sunday newspapers.